Lisa Vermunt

@AlzheimerAms | MD | PhD | biofluid biomarkers | autosomal dominant Alzheimer | proteomics | disease modelling | clinical trials

[Lisa Vermunt @LisaVermunt]

🙏Equally excited to share plasma glial fibrillary acidic protein (#GFAP) in #DIAN!
👉 see: https://t.co/EcPMyE5Xvw @alzdemjournals
👉 or go for the summary below by my dear co-author @PratishthaChat7
@AlzheimerAms @Alz_onderzoek @AmsNeuroscience #stichtingdioraphte

[Pratishtha Chatterjee @PratishthaChat7]

(1/6) Excited that our paper on plasma glial fibrillary acidic protein (#GFAP) in dominantly inherited #AlzheimersDisease is now out👉 https://t.co/fgWHENqkBr. @alzdemjournals. 🙏Many thanks @LisaVermunt @BrianGordon81 @RalphNMartins1 @CharlotteTeuni1 and all collaborators!

[Celeste Karch @karchlab]

Senescent glia link mitochondrial dysfunction and lipid accumulation https://t.co/X9efsGKwPA

[Brian Gordon @BrianGordon81]

Out now in @braincomms. Worked started over two years ago by @karin_meeker examining the relationship between 27 different AD biomarkers including MRI, PET, mass-spec, and plasma measures. https://t.co/GjXt8QaDdH

[Lisa Vermunt @LisaVermunt]

Trends in Postmortem Neurodegenerative and Cerebrovascular Neuropathologies Over 25 Years https://t.co/9zkUxAunQW

[Lisa Vermunt @LisaVermunt]

-> now online in @NatureComms
https://t.co/PQoYWr6RXc

[Lisa Vermunt @LisaVermunt]

The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT
@AlzheimerAms @AmsNeuroscience @BarcelonaBeta
Del Campo,@CharlotteTeuni1 and others

[Lisa Vermunt @LisaVermunt]

The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT
@AlzheimerAms @AmsNeuroscience @BarcelonaBeta
Del Campo,@CharlotteTeuni1 and others

[Alzheimercentrum Amsterdam (inactief) @AlzheimerAms]

NWO vroeg aan 5 wetenschappers welke oproep zij aan de #politiek doen op #Prinsjesdag. Onderzoeker @LisaVermunt van @AlzheimerAms wil overbrengen hoe belangrijk kennis is. “Zonder wetenschap geen nieuwe medicijnen.” Lees alle oproepen: https://t.co/hRZePxzMSR @NWONieuws

[Alzheimercentrum Amsterdam (inactief) @AlzheimerAms]

NWO Veni-beurs voor onderzoekers @AlzheimerAms: @LisaVermunt en Femke Feringa. Lees meer: https://t.co/NQUX391soU

[Lisa Vermunt @LisaVermunt]

Very grateful for my #Veni grant! A boost for our research line on familial #AD. By tracing #astrocyte failure with #laboratory tests, we will better understand how #Alzheimer evolves, to further precise forecasting and faster treatments. @ZonMw @AlzheimerAms @AmsNeuroscience

[NWO Funding @NWOFunding]

NWO has awarded Veni funding of up to EUR 280,000 to 188 promising researchers from the full breadth of science. This will allow the laureates to further develop their own research ideas over the next three years.
https://t.co/tUCSbytmva

[Alzforum @alzforum]

A trio of studies make a strong case that SORL1 is the fourth familial Alzheimer’s gene. @AarhusUni @amsterdamumc https://t.co/xRfKzHzNlB

[Lisa Vermunt @LisaVermunt]

The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT
@AlzheimerAms @AmsNeuroscience @BarcelonaBeta
Del Campo,@CharlotteTeuni1 and others

[Lisa Vermunt @LisaVermunt]

With shared pathophysiological CSF changes, ADAD study findings might be translatable to sporadic AD, which could greatly expedite therapy development.

[Lisa Vermunt @LisaVermunt]

Excited to share my newest senior author work in @Brain1878 !!!:
CSF #proteomics in autosomal dominant #Alzheimer’s disease highlights parallels with sporadic disease https://t.co/NxRV4OlXSq
@AlzheimerAms @GeneticAMS @AmsNeuroscience @CharlotteTeuni1 @OlinkProteomics

[Lisa Vermunt @LisaVermunt]

This CSF proteomics study demonstrates substantial biochemical similarities between ADAD and sporadic AD, suggesting involvement of the same biological processes. We identified several relatively novel proteins, which have potential as novel biomarkers.

[Carlos Cruchaga @ccrugom]

Our latest publication: Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease https://t.co/qn4MX3Y76F @WUADRC @Neuro_Genomics @WashUNeurology

[Jonathan Schott @jmschott]

Breaking news: @EliLillyandCo Phase 3 trial of Donanemab is positive, showing significant slowing on cognitive and functional outcomes. Now we have two positive trials showing effects of amyloid clearance in Alzheimer's disease-- hugely exciting times! https://t.co/pgpm34UMmv

[@BrainComms @braincomms]

Van Engelen et al. report that the use of urine as a matrix for neurofilament light chain (NfL) analysis to differentiate frontotemporal dementia from psychiatric disorders is not suitable and that urine NfL levels did not correlate with serum levels. https://t.co/vR9RMXUN9R

[Celeste Karch @karchlab]

I’m VERY excited to share our latest work with ⁦@LauraPiccio⁩. Led by the brilliant ⁦@FabiaFilipello⁩ identifying defects in iPSC-microglia from Nasu Hakola patients that were restored by targeting mTOR dependent and independent pathways ⁦ https://t.co/0Gfhp3b5EO

[Lisa Vermunt @LisaVermunt]

Biological enrichment for cell signalling and immune response pathways, with lower levels in fast progressing patients. Taken together, we present a novel progression biomarker identification framework and protein leads for prediction of cognitive decline in dementia.

[Lisa Vermunt @LisaVermunt]

👉 paper alert! Providing an accurate #prognosis for individual #dementia patients remains a challenge. We used machine learning techniques to identify #CSF #biomarkers that predict decline. https://t.co/mT55rfD7p4 @AmsNeuroscience @AlzheimerAms @CharlotteTeuni1 @OlinkProteomics

[Lisa Vermunt @LisaVermunt]

#TNFRSF4 and #TGF ββ-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. None of our top markers stood out as strong individual predictors of subsequent #cognitive #decline.